熊绍权教授运用“三味生火丹”治疗恶性肿瘤患者化疗相关难治性血小板减少症的经验总结

Summary of Professor Xiong Shaoquan’s experience in the treatment of refractory chemo-therapy-induced thrombocytopenia in patients with malignant tumors with“Sanwei Shenghuo Dan”

化疗相关难治性血小板减少症是多次化疗后引起的化疗副作用,其表现为难以逆转的骨髓造血功能障碍。常规使用重组人血小板生成素、白介素-11等促血小板因子已经难以达到理想临床疗效。熊绍权教授认为,本病多因瘀毒内结,引起脾肾等脏腑亏虚,反复化疗导致肾阴受损,阴损及阳,形成命门火衰,故提出本病的主要病机为“命门火衰,肾阴阳俱虚”,并创立“三味生火丹”辨治本病。此方由附子、黄精、大枣组成,并以1∶1∶1的比例配制组成,根据具体情况在此方基础上加减使用,一方面通过“补命门之火”壮肾中之阳,另一方面通过“健运中州”使中气得生,肾火旺盛则气血生长,中气充足则气血生化有源,血小板得以恢复正常。另附验案一则,以期为临床防治化疗相关难治性血小板减少症提供新的思路和方法。

Due to repeated chemotherapy in patients,refractory chemo-therapy-induced thrombocytopenia is a side effect of chemotherapy,which manifests as irreversible bone marrow hematopoietic dysfunction.Routine use of platelet-promoting factors such as recombinant human thrombopoietin,interleukin-11 and etc.has been difficult to achieve ideal clinical efficacy.Professor Xiong Shaoquan believes that the internal binding of static blood and poison caused the deficiency of the spleen kidney,and other viscera.Repeated chemotherapy leads to damaging the kidney yin and yin deficiency involving yang which results to the decline of vital gate fire.Therefore,Professor Xiong Shaoquan proposes that the main pathogenesis of this disease is“decline of vital gate fire and the deficiency of both kidney yin and yang”and created the“Sanwei Shenghuo Dan”to treat the disease.“Sanwei Shenghuo Dan”is composed of Aconiti Lateralis Radix Praeparata,Polygonati Rhizoma,Jujubae Fructus.The three herbs are prepared in a ratio of 1∶1∶1.According to the specific situation,“Sanwei Shenghuo Dan”need to be used in addition or subtraction others herbs on the basis of this prescription.On the one hand,replenishing the vital gate fire to strengthen the kidney yang;on the other hand,strengthening zhongzhou to produce the middle qi.When the kidney fire is strong,qi and blood grow,and when the middle qi is sufficient,the qi and blood biochemistry are active and the platelets can be restored to normal.A case study is attached in order to provide new ideas and methods for the clinical prevention and treatment of refractory chemo-therapy-induced thrombocytopenia.